Sound Processing Innovations in Adult and Paediatric Cochlear Implant Recipients.
Status
Conditions
Treatments
Details and patient eligibility
About
This is a feasibility, prospective with sequential enrolment, multicenter, clinical investigation in adults and paediatrics with a CE approved Nucleus cochlear implant.
Subjects older than 5 years will be included. Subjects will be screened and up to 120 eligible subjects will be recruited in the clinical investigation.
Subjects will attend scheduled study visits over a period up to 5 years in different sub-studies as described in the sub-study documentation.
A clinical setting can consist of therapeutic elements and evaluations. Subjects will be assessed with the commercially available Nucleus sound processor or via the xPC, NIC, etc. if required. Acute testing will be done where possible. Take home use will be applied when learning effects may play a significant role and to evaluate the acceptance of the new or improved sound coding algorithm or signal processing, in as many listening environments as possible. The subject might also be asked to complete questionnaires, to perform at-home tests etc. during this take home use and/or at the clinical visits. The time for a clinical visit will be limited to a maximum of 4 hours. The time in between clinical visits will vary with typical spacing of between 0 (acute) to 4 weeks.
The goals of this umbrella investigation are to measure hearing outcomes to assess performance and/or to achieve higher convenience for implant users and hearing care professionals. The outcomes of the study will guide Cochlear to select features for inclusion in future Nucleus cochlear implant systems and/or future models of care.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Users of a CE approved Nucleus cochlear implant, resulting in open set speech understanding.
- Paediatrics: Older than 5 years and <18 years when entering the study. (Belgium only) or
- Adults: ≥18 years when entering the study (Belgium and Australia).
- Subject/legally designated representative is fluent speaker in the language used for assessments.
- Willing and able to provide written informed consent (for paediatric populations this criterion applies to the parent/ legally designated representative).
Exclusion criteria
- Unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator.
- Additional health factors, known to the investigator, that would prevent or restrict participation in the audiological evaluations.
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
- Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.
Trial design
Primary purpose
Allocation
Interventional model
Masking
8 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Komal Arora; Taike Bruyneel
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal